JSC “Sintez” has expanded the production capacity of hydroxychloroquine recommended by the Ministry of health in the treatment protocols coronavirus infection. Now the hydroxychloroquine can be made at the site of JSC “Biocom” (subsidiary of JSC “Sintez” possesses the registration certificate for the drug) in Stavropol, and at the plant of the “Synthesis” in Kurgan. Together, these two plants can produce up to 300 000 units of hydroxychloroquine per week. The “Biokom”, which in April-may 2020 produced mainly hydroxychloroquine, can resume the production of other drugs on schedule.
“Expansion of production capacity of hydroxychloroquine at the expense of technology transfer on the ground of “Synthesis” in Barrow will allow us to meet the needs of Russian health in the product in case the diffusion rate COVID-19 again accelerated. This will also ensure continuity of supply to the retail market – this drug is used to treat rheumatoid arthritis and lupus, – says General Director of JSC “farm Center” – the managing organization of JSC “Synthesis” and JSC “Biocom” Sergei Fangs. He noted that from April 2020 the company sent to hospitals in different regions of Russia about 650 thousand packs of hydroxychloroquine. More than 18 thousand packages were shipped for sale in retail.
Earlier it became known that the regulatory agencies in the US and the EU abandoned the use of hydroxychloroquine in the treatment COVID-19 due to lack of evidence of its efficacy and security questions.